Suppr超能文献

酮康唑可有效逆转高耐药性KB细胞中的多药耐药性。

Ketoconazole effectively reverses multidrug resistance in highly resistant KB cells.

作者信息

Siegsmund M J, Cardarelli C, Aksentijevich I, Sugimoto Y, Pastan I, Gottesman M M

机构信息

Laboratory of Molecular Biology, DCBDC, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.

出版信息

J Urol. 1994 Feb;151(2):485-91. doi: 10.1016/s0022-5347(17)34999-6.

Abstract

The antifungal agent ketoconazole was found to overcome resistance to vinblastine and doxorubicin in multidrug resistant KB-V1 cells in vitro. These cells are several hundred-fold more resistant than the parental cell line KB-3-1. Ketoconazole had little or no effect on the parental KB-3-1 cells. The concentrations used to overcome drug resistance in vitro have already been safely used in vivo for treatment of fungal infections and in the monotherapy of hormone independent prostate carcinomas to block adrenal androgen production. Because of a possible beneficial effect of a combination of ketoconazole and a chemotherapeutic drug in multidrug resistant cancers, we examined a panel of 11 prostate carcinoma tissues for the expression of the MDR1 gene by an RNA-PCR assay. MDR1 expression was detectable, albeit at low levels, in 8 of the 11 tumors, suggesting a possible role of this gene in the drug resistance of prostate carcinomas. Our data suggest that ketoconazole might be useful in overcoming multidrug resistance in concentrations that are achievable in humans.

摘要

抗真菌药酮康唑在体外可克服多药耐药KB-V1细胞对长春碱和阿霉素的耐药性。这些细胞的耐药性比亲代细胞系KB-3-1高数百倍。酮康唑对亲代KB-3-1细胞几乎没有影响。在体外用于克服耐药性的浓度已在体内安全用于治疗真菌感染以及在激素非依赖性前列腺癌的单一疗法中阻断肾上腺雄激素的产生。由于酮康唑与化疗药物联合使用在多药耐药癌症中可能具有有益作用,我们通过RNA-PCR分析检测了一组11个前列腺癌组织中MDR1基因的表达。在11个肿瘤中的8个中可检测到MDR1表达,尽管水平较低,这表明该基因可能在前列腺癌的耐药性中起作用。我们的数据表明,酮康唑可能有助于在人体可达到的浓度下克服多药耐药性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验